Hospital Specialty Availability: Weeks 2 & 3 Update

Okay, here’s a revised and verified summary of the provided text, incorporating web searches to ensure accuracy and address potential errors. I’ve focused on providing a clear, concise, and correct overview of the drug availability issues.

Summary of Drug Availability – France – January 13, 2026

This report details supply issues for two injectable medications in France: Imukin and UN-ALFA. Both are experiencing shortages, and temporary provisions are being made using imported versions originally intended for the Spanish market.

1. Imukin 100 micrograms solution for injection

* Current Status: Limited stock remains. Further stock reduction is expected with the arrival of a new supply planned for the end of Febuary 2026.
* exceptional Provision: Imported Imukin (originally for the Spanish market) is being used as an exceptional and transitional measure since January 8, 2026.
* Expected delivery: Early March 2026.
* Import Details: The imported product is identical to the French version in terms of active substance, excipients, pharmaceutical form, and presentation (0.5 mL bottle). Differences are limited to packaging (box, labeling, instructions) and the absence of French-language notices and warning pictograms for pregnant women and drivers.
* CIP Code: 3400955776789 (for 0.5 mL bottle).
* Source: https://ansm.sante.fr/disponibilites-des-produits-de-sante/medicaments/imukin-100-microgrammes-solution-pour-injection (Accessed Jan 13, 2026)

2. UN-ALFA 1 microgramme/0,5 mL solution injectable IV en ampoule (alfacalcidol)

* Current Status: Out of stock at hospitals (“rupture”).
* Exceptional Provision: Imported Etalpha 1 microgram solution for injection (originally for the Spanish market) is being used as an exceptional and transitional measure.
* Distribution: Imported units are being distributed via a quota system.
* Expected Release Date: Undetermined.
* Import Details: The imported specialty complies with the French marketing authorization (AMM) regarding manufacturing processes. It is identical to the French version in terms of qualitative and quantitative composition,dosage,route,and method of administration.
* Source: https://ansm.sante.fr/disponibilites-des-produits-de-sante/medicaments/un-alfa-1-microgramme-0-5-ml-solution-injectable-iv-en-ampoule-alfacalcidol (Accessed Jan 13, 2026)

Vital Notes:

* All data is based on updates from the Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM – French National Agency for the Safety of Medicines and Health Products) as of January 13, 2026.
* Healthcare professionals should consult the linked ANSM pages and laboratory letters for the most up-to-date information and specific guidance.

Changes Made & Justification:

* Added direct links to ANSM pages: This provides immediate access to the authoritative source.
* Clarified “rupture”: Translated to “out of stock at hospitals” for better understanding.
* Formatted for readability: